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Abstract
Introduction. The significance of over-expression of epidermal growth factor receptor
(EGFR) in pancreatic carcinoma is unclear. In this study, we examined the association
between EGFR over-expression (membranous and cytoplasmic), the associated
histopathologic features and clinical outcomes in post resection pancreatic cancer
patients.

Methods. EGFR expression was determined immunohistochemically in 90 patients who
underwent resection for pancreatic cancer. Cytoplasmic expression was considered
positive if EGFR expression was seen in the cytoplasm in ≥10% of cells. Cell membrane
staining was scored from 0 to 3+, with 2+ and 3+ being considered as membrane overexpression. Overall survival and progression free survival were calculated using the
Kaplan-Meier method and survival curves were compared by the log-rank test.

Results. Out of 90 patients, 51 (57%) and 74 (68%) patients had membrane and
cytoplasmic EGFR over-expression respectively. There was a statistically significant
correlation between cell membrane EGFR over-expression and lymph node positivity

(p=0.03). Patients with membrane EGFR over-expression had a shorter median
progression free survival (10.7 vs. 17.0 months, p=0.02) and overall survival (15.9
months v 25.3 months, p=0.17). Cytoplasmic EFGR over-expression was not
significantly associated with recurrence or survival.

Conclusions. Membrane EGFR over-expression in resected pancreatic cancer patients
was associated with worse clinical outcomes than non over-expression.

Introduction
Pancreatic cancer is the fourth leading cause of cancer death in United States with 36,800
deaths and 43,140 incident cases estimated in 2010.{{193 Jemal,A. 2010}} Despite
therapy, the 5-year relative survival rate is approximately 6%. Due to relative lack of
early disease-specific symptoms, only a minority of the patients present with surgically
resectable disease. Even in patients who undergo pancreatectomy, the majority of the
patients develop recurrence with the 5-year overall survival of only 22.5%.{{193
Jemal,A. 2010}} Various genetic and molecular alterations are being investigated to
understand the basis of the disease aggressiveness.
Epidermal growth factor receptor (EGFR) is a 170 kDa protein belonging to ErbB
family of transmembrane tyrosine kinase growth factor receptors.{{199 Lemoine,N.R.
1992}} It is overexpressed in wide variety of solid tumors including breast, colon, lung
and prostate cancer.{{198 Nicholson,R.I. 2001}} Activation of EGFR in tumors results
in increased cell proliferation, reduced apoptosis, increased angiogenesis, increased

motility, invasion and metastatsis.{{200 Kopp,R. 2003}} The EGFR overexpression is
observed in 30% to 90% of pancreatic cancers, assayed by immunohistochemistry
techniques.{{201 Faller,B.A. 2009}} The cell membrane EGFR overexpression has been
demonstrated to be associated with various clinicopathological features. {{187
Yamanaka,Y. 1992; 188 Yamanaka,Y. 1993; 190 Dong,M. 1998; 183 Uegaki,K. 1997;
189 Gansauge,F. 1998; 196 Kuniyasu,H. 2001; 195 Tobita,K. 2003; 186 Ueda,S. 2004;
192 Bloomston,M. 2006; 194 Takikita,M. 2009; 191 Zhang,L. 2002}} However, the
effect of membrane EGFR overexpression on clinical outcomes is not well defined. The
association between cytoplasmic expression of EGFR and clinicopathologic features in
patients with pancreatic cancer has been reported in only one prior study.{{186 Ueda,S.
2004}}
In the current study, we investigated the association between cell membrane and
cytoplasmic EGFR overexpression and pathologic features in patients with primary
pancreatic cancer undergoing surgical resection. We also examined the role of EGFR
overexpression in the prognosis of patients with resected pancreatic cancer.

Methods
Patients
Ninety patients who underwent surgical resection for pancreatic cancer at Thomas
Jefferson University from April 2008 to April 2010 were included in the study. All the
cases were histologically diagnosed as ductal adenocarcinoma. The patients who did not
have any event (recurrence or death) were censored at the last date of follow-up. For
pathologic and immunohistochemical evaluation, 10% neutral-buffered formalin fixed

and paraffin-embedded tissue blocks from surgically resected specimens were processed
and 5-µm tissue sections were obtained. The tissue sections were stained using routine
hemotoxylin and eosin for pathologic diagnosis. The study was approved by Institutional
review Board at Thomas Jefferson University.

Immunohistochemistry
Immunohistochemical staining for EGFR was performed on a total of 90 cases
using the EGFR PharmDxTM kit (Dako). Specimens were evaluated for both cytoplasmic
and membranous immunostaining by a pathologist blinded to the results at Thomas
Jefferson University Hospital. Cytoplasmic overexpression was considered positive if
EGFR expression was noted in the cytoplasm in ≥10% of tumor cells. Cell membrane
EGFR staining was divided into four categories based on intensity and completeness of
staining as follows: 0 (no membrane staining or membrane staining in less than 10% of
tumor cells), 1+ (incomplete membrane staining in ≥ 10% of cells), 2+ (complete, weak
or moderate membrane staining in ≥ 10% of cells) and 3+ (complete, strong staining in ≥
10% of cells) (Figure 1). Scores of 2+ and 3+ were considered membranous EGFR
overexpression.

Statistical Analysis
Descriptive statistics were initially used to characterize the cohort. Chi-square test was
used to determine the association between EGFR overexpression and pathologic features.
Proportional hazard regression analyses were used to estimate hazard ratios (HR) and
95% confidence intervals (95% CI). Progression-free survival (PFS) and overall survival

(OS) was evaluated using Kaplan-Meier survival curves and differences in survival were
tested using log-rank tests. The two sided p-value of 0.05 was used for statistical
significance. All statistical analysis was done using SAS statistical software (SAS
Institute, Inc., Cary, NC).

Results
Table 1 describes the demographic and pathologic features of the 90 patients of this
study. The median age of the study cohort was 68 years (Range: 37-92 years). Thirty
seven (41.1%) patients were female and 53 (58.9%) patients were male. The number of
patients with AJCC stage I, II, III and IV were 8 (9.2%), 79 (87.8%), 1 (1.1%) and 2
(2.2%) respectively. Seventy seven patients underwent pylorus-preserving
pancreaticoduodenectomy and 13 patients underwent distal pancreatectomy. Cell
membrane EGFR overexpression was observed in 51 (56.7%) patients. Sixty four
(71.1%) patients had cytoplasmic EGFR overexpression. The relationship between EGFR
expression and pathologic features is summarized in Table 2. The association between
cell membrane EGFR overexpression and lymph node positivity was statistically
significant (p=0.03). No significant association of cell membrane EGFR overexpression
was found with tumor grade, local invasion, margin positivity, vascular invasion,
perineural invasion or stage. For cytoplasmic EGFR overexpression, statistically
significant association was observed with positive margin only (p<0.01).
The median PFS and OS for the study cohort were 11.8 months and 17.1 months
respectively. The median follow up time was 15.5 months. Fifty two (58%) patients had
either recurrence or death during the study follow up. Histological grade, lymphovascular

invasion and stage were significantly associated with survival. Figure 2 and 3
demonstrates the Kaplan-Meier PFS and OS curves stratified by membrane EGFR
overexpression respectively. Membrane EGFR overexpression was associated with
statistically significant shorter PFS (median PFS: 10.7 vs. 17.0 months, p=0.02). The
median OS for patients with cell membrane EGFR overexpression was also much shorter
than the OS in patients without EGFR overexpression (median OS: 15.9 months v 25.3
months, p=0.08), but this difference was not statistically significant, likely due to the
small patient numbers (Table 3). For recurrence and death, the HR for patients with cell
membrane EGFR overexpression (as compared to no EGFR overexpression) was 1.97
(95% CI: 1.09-3.55) and 1.82 (0.92-3.62) respectively. Cytoplasmic EGFR
overexpression did not correlate with PFS (median PFS: 11.7 months v 14.4 months,
p=0.30). The corresponding HR was 1.39 (0.74-2.61) without significant difference in
survival between patients with or without cytoplasmic EGFR staining (p=0.72). The
median OS was 17.1 months in patients with cytoplasmic EGFR overepression and 22.6
months in patients without EGFR overexpression (HR:1.13; 95% CI:0.57-2.27).

Discussion

Few retrospective studies have reported the relationship between EGFR overexpression
and clinical outcomes in patients with pancreatic cancer.{{187 Yamanaka,Y. 1992; 188
Yamanaka,Y. 1993; 190 Dong,M. 1998; 183 Uegaki,K. 1997; 189 Gansauge,F. 1998;
196 Kuniyasu,H. 2001; 195 Tobita,K. 2003; 186 Ueda,S. 2004; 192 Bloomston,M. 2006;
194 Takikita,M. 2009}} Membrane EGFR overexpression has been demonstrated to be

associated with higher stage and more aggressive tumors.{{195 Tobita,K. 2003; 191
Zhang,L. 2002}} However, the effect of EGFR overexpression on recurrence and
survival in patients with pancreatic cancer remains unclear. Only three out of ten studies
reported significantly worse survival in patients with membrane EFGR overexpression
than without it (Table 4).{{187 Yamanaka,Y. 1992; 188 Yamanaka,Y. 1993; 190
Dong,M. 1998}} In the current study, the resected pancreatic cancer patients with
membrane EGFR overexpression had worse clinical outcomes. The PFS was significantly
shorter and there was trend towards poorer survival with membrane EFGR
overexpression. There was significant association between lymph node involvement and
membrane EGFR overexpression.

To our knowledge, this is only the second study to evaluate the cytoplasmic EGFR
overexpression in resected pancreatic cancer patients. In the previous study, patients with
cytoplasmic EGFR overexpression had shorter overall survival.{{186 Ueda,S. 2004}}
However, in our study, we did not find any statistically significant difference in
recurrence or survival in relation to cytoplasmic EGFR overexpression. The cytoplasmic
staining of EGFR has been demonstrated to be associated with a poor prognosis in
patients with thyroid carcinoma and lung carcinoma. {{202 Piyathilake,C.J. 2002; 203
Akslen,L.A. 1993}} EGFR is internalized after the interaction with the ligand and
completion of growth stimulatory signals and is subsequently degraded in lysosmal
compartment. Thus, cellular localization pattern of EGFR may be of clinicopathologic
significance and its role as a prognostic and predictive marker needs to be further
evaluated.

Membrane EGFR expression is associated with poorer prognosis in head and neck,
ovarian, cervical, bladder, oesophageal, breast, colorectal and gastric cancers.{{198
Nicholson,R.I. 2001}} EGFR plays an important role in the growth of various human
cancers including pancreatic cancer.{{183 Uegaki,K. 1997}} The co-expression of
EGFR and its ligand may function as an autocrine loop to constantly stimulate cell
proliferation and blockade of EGFR activity has been shown to decrease the growth and
metastases of human pancreatic tumor xenografts and enhance the antitumor activity of
gemcitabine.{{199 Lemoine,N.R. 1992; 204 Bruns,C.J. 2000; 205 Ng,S.S. 2002}}
Erlotinib, a small molecule EGFR-specific tyrosine kinase inhibitor, has been
demonstrated to provide modest survival benefit in patients with locally advanced or
metastatic pancreatic cancer.{{185 Moore,M.J. 2007}} However, cetuximab, a
monoclonal EGFR antibody did not improve survival in patients with advanced
pancreatic cancer.{{197 Xiong,H.Q. 2004}} In neither of these studies, did membrane
EGFR expression predict tumor response to targeted therapy. Cytoplasmic EGFR
expression was not reported. This suggests that in advanced stage pancreatic cancer
patients, membrane EGFR expression is not a predictive marker for response to erlotinib
or cetuximab. The role of both membrane and cytoplasmic EGFR expression in the
adjuvant setting still needs to be examined.

Despite some recent advances in medical treatment, the prognosis of patients with
pancreatic cancer remains dismal. Surgery has curative potential but most of the patients
present with an advanced, unresectable stage. It is important to develop molecular

markers that can predict clinical outcomes. This may help to direct more aggressive
approaches in high risk patients. We think that future clinical trials involving EGFR
inhibitors should incorporate systematic evaluation of both cytoplasmic and membrane
EGFR expression.

Table 1. Clinicopathologic features of the study population
Parameter
Number (%)
Age >65 years
51 (56.7)
Gender
Male
53 (58.9)
Female
37 (41.1)
Race
White
82 (91.1)
Other
8 (8.9)
Site
Head
73 (81.1)
Body or/and tail
17 (18.9)
Grade
1
5 (5.6)
2
53 (58.9)
3
32 (35.6)
Stage
Ia
4 (4.6)
Ib
4 (4.6)
IIa
16 (17.8)
IIb
63 (70.0)
III
1 (1.1)
IV
2 (2.2)
Lymph node involvement
64 (71.1)
Pancreatitis
59 (65.6)
Cell membrane EGFR overexpression 51 (56.7)
Cytoplasmic EGFR overexpression
64 (71.1)

Table 2. Association between cell membrane and cytoplasmic EGFR overexpression and
pathologic features.
Parameter
Membrane overexpression Cytoplasmic overexpression
Present Absent
p
Present Absent
p
Local invasion
yes
43
31
0.55
52
22
0.70
no
8
8
12
4
Grade 3
yes
19
13
0.70
24
8
0.54
no
32
26
40
18
Margin positive
yes
17
6
0.05
22
1
<0.01
no
34
33
42
25
Vascular invasion
yes
27
18
0.52
30
15
0.35
no
24
21
34
11
Perineural invasion
0.29
21
0.17
57
36
42
yes
5
7
3
9
no
Lymph node
yes
41
23
0.03
42
22
0.07
no
10
16
22
4
Stage IIb or higher
yes
41
25
0.08
44
22
0.12
no

10

14

p<0.05 is considered statistically significant.
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4

Table 3. Association between EFGR expression and clinical outcomes
Progression Free Survival
Overall survival
Median HR 95% CI
p
Median HR 95% CI
p
(months)
(months)
Membrane EGFR
overexpression
Present
10.7
1.97 1.09-3.55 0.02 15.9
1.82 0.92-3.62 0.08
Absent
17.0
25.3
Cytoplasmic EGFR
Overexpression
Present
11.7
1.39 0.74-2.61 0.30 17.1
1.13 0.57-2.27 0.72
Absent
14.4
22.6
p<0.05 is considered statistically significant.

Table 4. Membrane EGFR overexpression and survival in patients with pancreatic
cancer.
Study
Number of
EGFR
Prognosis
patients
overexpression, (%)
Yamanka et
25
36
Decreased survival
al{{187
Yamanaka,Y.
1992; }}
Yamanka et
87
43
Decreased survival
al{{188
Yamanaka,Y.
1993; }}
Dong et
57
68
Decreased survival
al{{190
Dong,M. 1998;
}}
Uegaki et
86
44
Trend towards decreased survival
al{{183
Uegaki,K.
1997; }}
Gansauge et
82
54
No difference
al{{189
Gansauge,F.
1998; }}
Kuniyasi et
22
100
No difference
al{{196
Kuniyasu,H.
2001; }}
Tobita et
77
42
No difference
al{{195
Tobita,K. 2003;
}}
Ueda et
76
62
No difference
al{{186
Ueda,S. 2004;
}}

Bloomston et
al{{192
Bloomston,M.
2006; }}
Takikita et
al{{194
Takikita,M.
2009; }}
Current study

71

69

No difference

154

26

No difference

90

57

Trend towards decreased survival

Figure 1. Representative cases of pancreatic cancer demonstrating scores of membrane
EFGR expression. A, Score 0; B, Score 1: C, Score 2; D, Score 3.
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Figure 2. Progression free survival of pancreatic cancer patients stratified by membrane
EGFR overexpression

Figure 3. Overall survival of pancreatic cancer patients stratified by membrane EGFR
overexpression

